SUNDAY, JUNE 24, 2018

Novavax names vice president of finance

Novavax unveils management promotion
Novavax unveils management promotion | Courtesy of biology.usf.edu
Novavax, Inc., a clinical-stage vaccine company that specializes in the development, discovery and commercialization of recombinant nanoparticle vaccines and adjuvants, named Chris Dunne as its new vice president of finance on June 15.

Dunne began working at Novavax in January 2010 as executive director and was  responsible for the company’s financial reporting.

Before working at Novavax, Dunne was senior director of finance at Ore Pharmaceuticals, a publicly traded biotechnology company previously called Gene Logic. Dunne worked here from 1996 to 2010.

Dunne earlier worked as a senior project accountant at Akridge. While there, he was in charge of the accounting activities in the portfolio of commercial real estate partnerships and corporations based in Washington, D.C. He also managed the audits for several private and public companies at Deloitte & Touche, LLP. In addition, he prepared initial public offerings and SEC reporting.

Dunne attended the University of Maryland and received a degree in business management. He is a Certified Public Accountant.

Dunne was an important part of the Novavax team that made a contract with the Department of Health and Human Services' Biomedical Advanced Research and Development Authority worth $179 million. His leadership abilities in accounting and finance have helped Novavax grow as a company.

Organizations in this Story

Novavax

Want to get notified whenever we write about Novavax ?
Next time we write about Novavax, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.